DexCom (DXCM)
(Delayed Data from NSDQ)
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Zacks News
Big Tech Earnings & Economic Numbers: 3 Ways to Survive the Week Ahead
by Andrew Rocco
Many of the FANG stocks are slated to report earnings this week. Today, we will lay out how investors can best navigate the action packed week ahead.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter results likely to reflect rising volumes across all channels.
Zacks Investment Ideas feature highlights: Nvidia, First Solar, Intuitive Surgical, Dexcom and Asure Software
by Zacks Equity Research
Nvidia, First Solar, Intuitive Surgical, Dexcom and Asure Software are part of the Zacks Investment Ideas article.
Riding the Wave: These 3 Industry Groups are Making a Splash with Expected Money Inflows
by Andrew Rocco
Markets have been known to have periods of "nasty" industry group rotation. Get ahead of the curve with these 3 under-the-radar groups.
Are Medical Stocks Lagging DexCom (DXCM) This Year?
by Zacks Equity Research
Here is how DexCom (DXCM) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $116.18, moving +1.56% from the previous trading session.
AngioDynamics (ANGO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -200% and 2.28%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
Dexcom (DXCM) Launches G6 Glucose Monitoring System in Canada
by Zacks Equity Research
Dexcom (DXCM) announces the availability of standard of care in diabetes management - G6 CGM system - for type 1 and 2 patients with basal and bolus insulin or using an insulin pump in Canada.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Should Vanguard Mid-Cap Growth ETF (VOT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VOT
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $118.98, moving +1.51% from the previous trading session.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
DexCom (DXCM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $113.72, moving +0.49% from the previous trading session.
DexCom (DXCM) Stock Moves -0.59%: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $112.08, marking a -0.59% move from the previous day.
5 Stocks That Powered Nasdaq ETF Last Week
by Sweta Killa
The tech-heavy Nasdaq Composite Index outperformed last week, gaining 2.6%, while the S&P 500 and the Dow Jones were up 1.9% and 1.7%, respectively.
DexCom (DXCM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $122.92, moving +1.39% from the previous trading session.
Universal Health (UHS) Q4 Earnings Beat on Solid Segments
by Zacks Equity Research
Universal Health's (UHS) fourth-quarter results indicate growing revenues in its segments resulting from higher patient volumes. Management expects adjusted EPS within $9.50-$10.50 for 2023.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Community Health (CYH) Q4 Earnings Beat on Strong Admissions
by Zacks Equity Research
Community Health's (CYH) fourth-quarter results indicate growing patient volumes. However, management estimates net loss per share to lie between 65 cents and 5 cents in 2023.
DexCom (DXCM) Q4 Earnings Beat Estimates, Volumes Remain Strong
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
DexCom (DXCM) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 30.77% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?